JPS53136513A - Stabilization of prostaglandin-x-related compounds - Google Patents

Stabilization of prostaglandin-x-related compounds

Info

Publication number
JPS53136513A
JPS53136513A JP5127877A JP5127877A JPS53136513A JP S53136513 A JPS53136513 A JP S53136513A JP 5127877 A JP5127877 A JP 5127877A JP 5127877 A JP5127877 A JP 5127877A JP S53136513 A JPS53136513 A JP S53136513A
Authority
JP
Japan
Prior art keywords
prostaglandin
stabilization
related compounds
clathrating
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5127877A
Other languages
English (en)
Japanese (ja)
Inventor
Masaki Hayashi
Katsuhiko Shiyudo
Yoshitsugu Iijima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to JP5127877A priority Critical patent/JPS53136513A/ja
Priority to US05/902,118 priority patent/US4479944A/en
Priority to FR7813047A priority patent/FR2389375B1/fr
Priority to DE19782819447 priority patent/DE2819447A1/de
Priority to GB34230/80A priority patent/GB1604162A/en
Priority to GB18064/78A priority patent/GB1604161A/en
Priority to FR7831038A priority patent/FR2398498A1/fr
Publication of JPS53136513A publication Critical patent/JPS53136513A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP5127877A 1977-05-06 1977-05-06 Stabilization of prostaglandin-x-related compounds Pending JPS53136513A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP5127877A JPS53136513A (en) 1977-05-06 1977-05-06 Stabilization of prostaglandin-x-related compounds
US05/902,118 US4479944A (en) 1977-05-06 1978-05-02 Composition containing PGI2 analogs stabilized
FR7813047A FR2389375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-05-06 1978-05-03
DE19782819447 DE2819447A1 (de) 1977-05-06 1978-05-03 Prostaglandin-analoge enthaltende praeparate
GB34230/80A GB1604162A (en) 1977-05-06 1978-05-05 Compositions containing prostaglandin analogues
GB18064/78A GB1604161A (en) 1977-05-06 1978-05-05 Compositions containing prostaglandin analogues
FR7831038A FR2398498A1 (fr) 1977-05-06 1978-11-02 Compositions stabilisees a usage pharmacologique contenant un analogue de la prostaglandine i2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5127877A JPS53136513A (en) 1977-05-06 1977-05-06 Stabilization of prostaglandin-x-related compounds

Publications (1)

Publication Number Publication Date
JPS53136513A true JPS53136513A (en) 1978-11-29

Family

ID=12882465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5127877A Pending JPS53136513A (en) 1977-05-06 1977-05-06 Stabilization of prostaglandin-x-related compounds

Country Status (5)

Country Link
US (1) US4479944A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS53136513A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2819447A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2389375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB1604162A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013231038A (ja) * 2013-06-04 2013-11-14 Techfields Biochem Co Ltd 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU179141B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1977-09-23 1982-08-28
DE2811950A1 (de) * 1978-03-18 1979-12-13 Hoechst Ag Neue analoga von prostacyclin
US4430340A (en) * 1978-07-17 1984-02-07 The Upjohn Company Stabilization of PGI2 compounds with surfactants
DE2902809A1 (de) 1979-01-25 1980-08-07 Hoechst Ag Neue analoga von prostacyclin
US4211793A (en) * 1979-03-19 1980-07-08 American Cyanamid Company Triethyl citrate solutions of PGE-type compounds
US4303671A (en) 1980-07-10 1981-12-01 The Upjohn Company Albumin stabilized prostacyclin
JPS6013779A (ja) * 1983-07-05 1985-01-24 Green Cross Corp:The プロスタグランジンｉ↓２誘導体
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1970-06-10 1975-02-04
US3829579A (en) * 1971-11-01 1974-08-13 Upjohn Co Stable solutions of pge-type compounds
DE2357953A1 (de) * 1973-11-21 1975-05-28 Hoechst Ag Neue, natuerlich nicht vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
JPS51128948A (en) * 1975-10-20 1976-11-10 Ono Pharmaceut Co Ltd Prostaglandin analogues, process for preparing thereof and pharmaceuti cal compositions containing said analofues
IL51189A (en) * 1976-02-04 1985-08-30 Upjohn Co Prostaglandin analogs
GB1595056A (en) * 1976-10-12 1981-08-05 Wellcome Found Pharmaceutical combination
JPS5395958A (en) * 1977-01-31 1978-08-22 Ono Pharmaceut Co Ltd Prostaglandin analogues and process for their preparation
US4178367A (en) * 1977-02-21 1979-12-11 Ono Pharmaceutical Co. Ltd. Prostaglandin I2 analogues
HU179141B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1977-09-23 1982-08-28
JPS54115368A (en) * 1978-03-01 1979-09-07 Ono Pharmaceut Co Ltd Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013231038A (ja) * 2013-06-04 2013-11-14 Techfields Biochem Co Ltd 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ

Also Published As

Publication number Publication date
GB1604161A (en) 1981-12-02
FR2389375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-08-06
FR2398498B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-12-17
FR2398498A1 (fr) 1979-02-23
DE2819447A1 (de) 1978-11-09
GB1604162A (en) 1981-12-02
FR2389375A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1978-12-01
US4479944A (en) 1984-10-30

Similar Documents

Publication Publication Date Title
JPS53136513A (en) Stabilization of prostaglandin-x-related compounds
JPS5341428A (en) Miticidal composition
JPS51132242A (en) Light stabilising composition for synthetic resin
JPS5233624A (en) Preparation of leucylnitroagmatines
JPS5430135A (en) 4-hydroxy-4-methyl-cyclohexene-2-one-1
JPS522193A (en) Light warning device
JPS537683A (en) Purification of pyridoxine
JPS51111309A (en) Tape drioing mechanism
JPS5268116A (en) Preparation of alkoxyalkylidene compounds
JPS5386009A (en) Preparation
JPS5435208A (en) Stabilization of prostaglandin and prostaglandin-ramily compound
JPS5277003A (en) Stabilization process of peroxyketones
JPS51136689A (en) Process for preparing trithiane compounds
JPS5344634A (en) Carcinostatic agent
JPS53148519A (en) Preparation of solid medicine containing gefarnate
JPS53148536A (en) Carcinostatic agent containing trans-4-aminomethylcyclohexane-1-carboxylic acid derivative
JPS52100483A (en) Isoleucomycin a5
JPS5247098A (en) Process for preparing modified polyesters
JPS5222081A (en) Preparation of stabilised polyolefin
JPS52136993A (en) Preparation of l-cystein derivatives
JPS51137533A (en) Game
JPS52111554A (en) Anthracycline type compounds
JPS5219445A (en) Air-cooler
JPS51117366A (en) Vacuum dehydrator
JPS5357256A (en) Cyano type norbornene derivative composition